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The SOR (Standards, Options, Recommendations) clinical
practice guideline program of the FNCLCC (French National
Federation of Cancer Centres) described in this supplement is a
significant accomplishment with several lessons for guideline
developers around the world (Fervers et al, 2000). 
The FNCLCC is a formal association with an administrative
structure, including an administrative board consisting of the
Directors of each of the 20 member independent Comprehensive
Cancer Centres in France’s public health system. The FNCLCC
Centres have developed together programmatic initiatives that
demonstrate the value of a cooperative and coordinated approach
to addressing the cancer problem on a national scale. Each Centre
contributes both financial and human resources, and they share
clinical information. Such an initiative requires imaginative and
dedicated leadership to keep the partners at the table for the
common welfare of the system. 
A programmatic approach to guideline development provides
opportunities for addressing challenges that currently face the ad
hoc nature of the guideline movement worldwide. Some of these
challenges include: avoiding the duplication of effort where
possible across guideline development groups; improving the
connection between the development phase and the equally impor-
tant ‘aftercare phases’ (maintenance, dissemination, implementa-
tion, evaluation and reporting) of guidelines; promoting bottom-up
as opposed to the generally less effective top-down approach of
many guideline development projects; improving opportunities for
quality improvement and efficiency over time; suggesting oppor-
tunities for research collaborations. 
DUPLICATION OF EFFORT IN GUIDELINE
DEVELOPMENT 
Motivated by a desire to ‘claim intellectual territory’ and to main-
tain control over their own destinies, health professional societies
have entered into the guideline development game. Many of these
efforts began simultaneously, resulting in the production of guide-
lines that caused confusion in the field, especially when guidelines
varied in quality and were inconsistent in their recommendations.
This, combined with the huge effort and expense of developing an
evidence-based guideline, has caused developers to realize the
waste involved in ad hoc approaches. 
Programmatic initiatives such as SOR provide the opportunity
to think through guideline priorities and harness cooperation 
from a variety of sources, in order to develop their own docu-
ments, or adopt those of others’, that are of high quality and
acceptable to stakeholders. A programmatic approach provides the
opportunity for a formal process of guideline ‘adoption’ or
‘endorsement’ by which programs would consider guidelines
produced by other groups, and then set criteria for their use locally. 
The process of endorsement/adoption begins during the liter-
ature searching phase of the development process, which ought
to include the location of existing documents that might be
relevant, thus avoiding the full-blown effort of starting from
scratch. In this way, the generalizable features of already devel-
oped guidelines (i.e. the synthesized evidence) could be shared,
with local groups developing recommendations that are unique
to local interpretations of the evidence and consistent with local
circumstances and values. Through such mechanisms, the
overall costs of the systematic overviews (Mulrow, 1994) that
are at the heart of evidence-based recommendations, can be
reduced. 
LINKING DEVELOPMENT WITH
IMPLEMENTATION AND EVALUATION 
At the start, guideline efforts almost always underestimated the
costs and effort required to develop documents that were truly
‘evidence-informed’ (Sackett et al, 1996) (a more appropriate term
than ‘evidence-based’). Ad hoc panels of otherwise busy volun-
teers were assembled to address clinical conditions comprehen-
sively. By the time the guidelines were completed, the participants
were eager to see them published, but had little interest in their
‘aftercare’. Guideline ‘aftercare’ refers to the important activities
of evidence updating (maintenance), dissemination, implementa-
tion, evaluation and reporting. Using the ad hoc approach, what-
ever financial resources were allocated to the project became
quickly consumed during the development phase, leaving little
available for aftercare. 
The programmatic approach taken by SOR demonstrates the
potential value of a balanced portfolio of aftercare activities that
can be planned within predictable budgetary constraints. For
example, the program could theoretically decide what proportion
of its resources to use in any given year for the development of
new guidelines, for maintenance of existing ones, or for evaluation
(Ray-Coquard et al, 1997). The financial resources within SOR
have become constrained, with additional funding needed for
detailed implementation and evaluation. These are being planned
to occur within regional networks. 
A programmatic approach allows for strategic linkage between
development and implementation phases. For SOR, part of the
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opment phase. Too often, guideline development, dissemination and
implementation are conceptualized as sequential, as opposed to
interacting phases along the path of a guideline’s life-cycle. 
‘TOP-DOWN’ VS ‘BOTTOM-UP’ GUIDELINE
DEVELOPMENT STRATEGIES 
While the SOR guideline development process adheres quite
rigorously to ‘evidence-informed’ principles, it also respects expe-
rience through practitioner feedback and the use of expert
consensus as equally legitimate inputs into clinical recommenda-
tions (Browman, 1999; Browman et al, 1999). The acknowledge-
ment of the importance of blending clinical expertise with research
evidence is an important step forward in advancing the evidence-
informed approach as one that is practical and responsive. This
approach is also more likely to achieve ‘buy-in’ from those who
are expected to abide by the recommendations (Cabana et al,
1999). It is this ‘bottom-up’ feature of SOR that links implementa-
tion with development, and the success of this approach by SOR
has been explicitly acknowledged by French health authorities. 
OPPORTUNITIES FOR QUALITY IMPROVEMENT
AND EFFICIENCY OVER TIME 
An important feature of the FNCLCC guideline development
model is the use of a more or less permanent slate of panels,
consisting of members who remain together for an extended time.
This provides members with the opportunity to learn together so
that their work improves over time in both quality and efficiency.
Participation involves broad representation of expertise, including
the guideline developers and expert reviewers from Cancer
Centres, partner universities, general hospitals (all public sector)
and private clinics. This enables regions to enhance dissemination
of the message using opinion leaders who are part of the develop-
ment process. As such, the process may serve as a valuable educa-
tional vehicle that can influence the entire culture of the cancer
system. 
Another important characteristic of the SOR model is the
‘methodology resource group’. This enabling strategy makes
guideline developers feel supported in their work, and also
contributes to their continuing education as consumers and users
of healthcare research. The methods resource group serves a
quality-control function, to ensure that appropriate scientific
methods are used to minimize bias in how the evidence is located,
synthesized and interpreted, and it can also contribute to the main-
tenance phase of aftercare. 
OPPORTUNITIES FOR RESEARCH
COLLABORATIONS 
The programmatic nature of SOR positions it well to contribute to
national and international research efforts to improve the guideline
movement and the quality of guideline documents. Three aspects
of the SOR/FNCLCC project demonstrate where such collabora-
tions might be useful. 
i) In 1994, Dr Beatrice Fervers of the FNCLCC visited McMaster
University in Hamilton, Canada to review the methods and organi-
zation of the Cancer Care Ontario Clinical Practice Guideline
Initiative (Browman et al, 1995; Evans et al, 1997). At that time,
both initiatives were at a similar stage of evolution. Despite the
programs having evolved independently in different countries,
the program leaders noted remarkable parallels in the con-
ceptualization, implementation and barriers associated with their
approaches. This led to a comparative analysis of programs in
different medical cultures from Canada and France, suggesting
that an evidence-informed programmatic approach to guidelines
within an identifiable cancer system may be generalizable (Fervers
et al, 1997). 
The collaboration has also provided insights into the legitimate
reasons for inconsistency of guideline recommendations based on
the same evidence, because of differences in national and medical
cultural perspectives. One important cultural difference is the
extensive involvement of lay people (community representatives)
by the Ontario initiative, and their lack of representation in SOR. 
ii) Each guideline produced by SOR is comprehensive in its
attempt to cover all aspects of the management of a particular clin-
ical condition. This is similar to national guidelines produced in
Australia and New Zealand, but is in contrast with other programs,
such as Cancer Care Ontario which uses guidelines to inform only
narrow aspects of a condition, relating to a specific clinical deci-
sion of high priority. Canada’s Steering Committee on Clinical
Practice Guidelines for the Care and Treatment of Breast Cancer
took a middle ground by producing ten specific guideline docu-
ments and then consolidating them as chapters within a more
comprehensive document (Steering Committee on Clinical
Practice Guidelines for the Care and Treatment of Breast Cancer,
1998a–k). Although there is value in a comprehensive approach,
the key information and recommendations pertaining to specific
decisions are often difficult to find without companion documents.
SOR deals with this through the use of clinical algorithms as a
practical guide for the clinician (Fervers et al, 1995). Furthermore,
the updating process allows a focus on specific clinical questions
of high priority that can be easily linked to the comprehensive
document. 
Also, guideline developers may have preferences as to whether
they attack a problem comprehensively from the beginning or in
more easily manageable priority chunks, and this may influence
their motivation and work habits during the phase of development.
Finally, there needs to be consideration of the relative value of
clinical guidelines in areas where evidence is strong or weak. The
objectives of individual guidelines that are designed to influence
practice where evidence is strong may be strategically different
from the objectives of guidelines intended to influence practice
where evidence is weak. This can be a challenge for comprehen-
sive guidelines because of the variation in quality of the evidence
at different points along the management continuum of a disease.
For the many situations where evidence may be weak, a program-
matic approach can be used to implement formal consensus
processes for developing recommendations that are credible. 
iii) The use of ‘levels of evidence’ to communicate the quality of
healthcare research results available to inform a clinical recom-
mendation is a feature of virtually all ‘evidence-informed’ guide-
line processes (Cook et al, 1995). However, the application of this
approach may suffer because it tends to be formulaic, and varies
widely from one group to another. 
The ‘levels of evidence’ construct was originally conceived as a
form of descriptive shorthand. It was intended to convey, through
categorization, the quality of evidence available, based on the
rigor of the design of the research used to generate it. 
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of the best available evidence that addresses a particular problem.
For example, results from large randomized controlled trials of an
intervention vs control for a given condition (level I evidence)
trumps lower quality evidence, and it is therefore redundant to
qualify a recommendation by more than one level of evidence as
some guidelines do. But, even evidence categorized as of high
quality (e.g. randomized controlled trials) can vary in quality
depending on other design features of the research (e.g. blinding,
concealment of allocation and adequacy of follow-up). 
Levels of evidence have been used to grade the recommenda-
tions in guidelines. Such grades are intended to reflect the confi-
dence with which a recommendation can be made. The SOR
documents blend the traditional levels of evidence with grades of
recommendations, which can create confusion. Our experience is
that clinicians often have difficulty in making the correlation
between a level of evidence and a recommendation grade. This is
because of the variable quality of research evidence within levels,
and the problem of generalizing the results of some trials of high
quality. 
The use of ‘levels of evidence’ as a shorthand descriptive tool
was never intended to provide only positive support for recom-
mendations about interventions. For example, evidence classified
as poor (e.g. case reports or case series) is usually a signal that the
evidence ought to be seriously challenged as a support for a posi-
tive recommendation. Yet many guideline developers (in their
enthusiasm) use such low quality evidence as justification to
recommend an intervention, as opposed to justifying its rejection.
Some guideline development groups actually rate ‘expert opinion’
with a level of evidence. This may provide a veneer of rigor that
does not actually exist, and reduces the usefulness of the ‘levels of
evidence’ approach. 
Some guideline programs have attached lower levels of
evidence to recommendations, for the apparent sake of complete-
ness. Often, such a recommendation (e.g. the use of a multidisci-
plinary approach, or the routine use of a complete blood count in
initial patient evaluation) will never be tested in a trial, nor may it
be worth testing, and it does not require slavish adherence to a
formulaic framework. 
These issues highlight the need for more research into how to
appropriately use levels of evidence, how to link them, if at all,
with clinical recommendations and how to report recommenda-
tions within a guideline. Programs like the SOR are well posi-
tioned to make valuable and insightful contributions to improving
the overall quality of clinical guidelines, as an evolving healthcare
technology for cancer (Browman et al, 1997). The achievements of
the SOR program mark its investigators as potentially valuable
contributors to international collaborations for improving the
development and aftercare of clinical practice guidelines. 
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